000902026 001__ 902026
000902026 005__ 20211130111054.0
000902026 0247_ $$2doi$$a10.1038/s41598-021-00193-x
000902026 0247_ $$2Handle$$a2128/28838
000902026 0247_ $$2altmetric$$aaltmetric:115556233
000902026 0247_ $$2pmid$$a34675225
000902026 0247_ $$2WOS$$aWOS:000709931300019
000902026 037__ $$aFZJ-2021-03984
000902026 041__ $$aEnglish
000902026 082__ $$a600
000902026 1001_ $$0P:(DE-HGF)0$$aRosen, Jurij$$b0$$eCorresponding author
000902026 245__ $$aPrognostic value of pre-irradiation FET PET in patients with not completely resectable IDH-wildtype glioma and minimal or absent contrast enhancement
000902026 260__ $$a[London]$$bMacmillan Publishers Limited, part of Springer Nature$$c2021
000902026 3367_ $$2DRIVER$$aarticle
000902026 3367_ $$2DataCite$$aOutput Types/Journal article
000902026 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1635144371_28704
000902026 3367_ $$2BibTeX$$aARTICLE
000902026 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000902026 3367_ $$00$$2EndNote$$aJournal Article
000902026 520__ $$aIn glioma patients, complete resection of the contrast-enhancing portion is associated with improved survival, which, however, cannot be achieved in a considerable number of patients. Here, we evaluated the prognostic value of O-(2-[18F]-fluoroethyl)-L-tyrosine (FET) PET in not completely resectable glioma patients with minimal or absent contrast enhancement before temozolomide chemoradiation. Dynamic FET PET scans were performed in 18 newly diagnosed patients with partially resected (n = 8) or biopsied (n = 10) IDH-wildtype astrocytic glioma before initiation of temozolomide chemoradiation. Static and dynamic FET PET parameters, as well as contrast-enhancing volumes on MRI, were calculated. Using receiver operating characteristic analyses, threshold values for which the product of paired values for sensitivity and specificity reached a maximum were obtained. Subsequently, the prognostic values of FET PET parameters and contrast-enhancing volumes on MRI were evaluated using univariate Kaplan–Meier and multivariate Cox regression (including the MTV, age, MGMT promoter methylation, and contrast-enhancing volume) survival analyses for progression-free and overall survival (PFS, OS). On MRI, eight patients had no contrast enhancement; the remaining patients had minimal contrast-enhancing volumes (range, 0.2–5.3 mL). Univariate analyses revealed that smaller pre-irradiation FET PET tumor volumes were significantly correlated with a more favorable PFS (7.9 vs. 4.2 months; threshold, 14.8 mL; P = 0.012) and OS (16.6 vs. 9.0 months; threshold, 23.8 mL; P = 0.002). In contrast, mean tumor-to-brain ratios and time-to-peak values were only associated with a longer PFS (P = 0.048 and P = 0.045, respectively). Furthermore, the pre-irradiation FET PET tumor volume remained significant in multivariate analyses (P = 0.043), indicating an independent predictor for OS. Our results suggest that pre-irradiation FET PET parameters have a prognostic impact in this subgroup of patients.
000902026 536__ $$0G:(DE-HGF)POF4-5252$$a5252 - Brain Dysfunction and Plasticity (POF4-525)$$cPOF4-525$$fPOF IV$$x0
000902026 588__ $$aDataset connected to CrossRef, Journals: juser.fz-juelich.de
000902026 7001_ $$0P:(DE-Juel1)131627$$aStoffels, Gabriele$$b1$$ufzj
000902026 7001_ $$0P:(DE-Juel1)145110$$aLohmann, Philipp$$b2$$ufzj
000902026 7001_ $$0P:(DE-HGF)0$$aBauer, Elena K.$$b3
000902026 7001_ $$0P:(DE-HGF)0$$aWerner, Jan-Michael$$b4
000902026 7001_ $$0P:(DE-Juel1)190394$$aWollring, Michael$$b5$$ufzj
000902026 7001_ $$0P:(DE-HGF)0$$aRapp, Marion$$b6
000902026 7001_ $$0P:(DE-HGF)0$$aFelsberg, Jörg$$b7
000902026 7001_ $$0P:(DE-Juel1)173675$$aKocher, Martin$$b8$$ufzj
000902026 7001_ $$0P:(DE-Juel1)131720$$aFink, Gereon R.$$b9$$ufzj
000902026 7001_ $$0P:(DE-Juel1)131777$$aLangen, Karl-Josef$$b10$$ufzj
000902026 7001_ $$0P:(DE-Juel1)143792$$aGalldiks, Norbert$$b11$$ufzj
000902026 773__ $$0PERI:(DE-600)2615211-3$$a10.1038/s41598-021-00193-x$$gVol. 11, no. 1, p. 20828$$n1$$p20828$$tScientific reports$$v11$$x2045-2322$$y2021
000902026 8564_ $$uhttps://juser.fz-juelich.de/record/902026/files/Rosen_2021_Sci%20Rep_Prognostic%20value%20of....pdf$$yOpenAccess
000902026 909CO $$ooai:juser.fz-juelich.de:902026$$pdnbdelivery$$pdriver$$pVDB$$popen_access$$popenaire
000902026 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)131627$$aForschungszentrum Jülich$$b1$$kFZJ
000902026 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)145110$$aForschungszentrum Jülich$$b2$$kFZJ
000902026 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)190394$$aForschungszentrum Jülich$$b5$$kFZJ
000902026 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)173675$$aForschungszentrum Jülich$$b8$$kFZJ
000902026 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)131720$$aForschungszentrum Jülich$$b9$$kFZJ
000902026 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)131777$$aForschungszentrum Jülich$$b10$$kFZJ
000902026 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)143792$$aForschungszentrum Jülich$$b11$$kFZJ
000902026 9131_ $$0G:(DE-HGF)POF4-525$$1G:(DE-HGF)POF4-520$$2G:(DE-HGF)POF4-500$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$9G:(DE-HGF)POF4-5252$$aDE-HGF$$bKey Technologies$$lNatural, Artificial and Cognitive Information Processing$$vDecoding Brain Organization and Dysfunction$$x0
000902026 9141_ $$y2021
000902026 915__ $$0LIC:(DE-HGF)CCBY4$$2HGFVOC$$aCreative Commons Attribution CC BY 4.0
000902026 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2021-02-03
000902026 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2021-02-03
000902026 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2021-02-03
000902026 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2021-02-03
000902026 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2021-02-03
000902026 915__ $$0StatID:(DE-HGF)1040$$2StatID$$aDBCoverage$$bZoological Record$$d2021-02-03
000902026 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bSCI REP-UK : 2019$$d2021-02-03
000902026 915__ $$0StatID:(DE-HGF)0501$$2StatID$$aDBCoverage$$bDOAJ Seal$$d2021-02-03
000902026 915__ $$0StatID:(DE-HGF)0500$$2StatID$$aDBCoverage$$bDOAJ$$d2021-02-03
000902026 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2021-02-03
000902026 915__ $$0StatID:(DE-HGF)0700$$2StatID$$aFees$$d2021-02-03
000902026 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2021-02-03
000902026 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5$$d2021-02-03
000902026 915__ $$0StatID:(DE-HGF)0510$$2StatID$$aOpenAccess
000902026 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2021-02-03
000902026 915__ $$0StatID:(DE-HGF)0561$$2StatID$$aArticle Processing Charges$$d2021-02-03
000902026 915__ $$0StatID:(DE-HGF)1150$$2StatID$$aDBCoverage$$bCurrent Contents - Physical, Chemical and Earth Sciences$$d2021-02-03
000902026 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2021-02-03
000902026 915__ $$0StatID:(DE-HGF)0320$$2StatID$$aDBCoverage$$bPubMed Central$$d2021-02-03
000902026 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2021-02-03
000902026 920__ $$lyes
000902026 9201_ $$0I:(DE-Juel1)INM-3-20090406$$kINM-3$$lKognitive Neurowissenschaften$$x0
000902026 9201_ $$0I:(DE-Juel1)INM-4-20090406$$kINM-4$$lPhysik der Medizinischen Bildgebung$$x1
000902026 980__ $$ajournal
000902026 980__ $$aVDB
000902026 980__ $$aUNRESTRICTED
000902026 980__ $$aI:(DE-Juel1)INM-3-20090406
000902026 980__ $$aI:(DE-Juel1)INM-4-20090406
000902026 9801_ $$aFullTexts